Integer Holdings Corporation delivered a strong performance in Q4 2025, with sales increasing 5% to $472 million and adjusted EPS rising 23% to $1.76 per share. The company also repurchased 698,356 common shares for $50 million, demonstrating confidence in its financial health and future prospects.
Sales increased 5% to $472 million in Q4 2025, reflecting solid growth across various segments.
Adjusted EPS grew by 23% to $1.76 per share in Q4 2025, indicating improved profitability.
The company repurchased 698,356 common shares for $50 million, returning value to shareholders.
Cardio & Vascular sales increased 11% in Q4 2025, driven by acquisitions and strong demand in Neurovascular.
Integer's 2026 outlook maintains the midpoint of sales growth and the high end of adjusted EPS growth from the October outlook, with continued expectations for above-market organic sales growth in 2027.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance